According to a new report, published by KBV research, The Global Human Microbiome Market size is expected to reach $1.1 Billion by 2028, rising at a market growth of 32.2% CAGR during the forecast period.
The Diagnostic Tests segment is showcasing a CAGR of 33.3% during (2022 - 2028). The increasing growth of the segment is owing to the precision of human microbiomes in diagnostic tests. Microbiome testing can offer basic as well as a complete knowledge of the gut of a patient. In addition, human microbiomes measure the presence of microorganisms in the gastrointestinal tract of the patient.
The Infectious Diseases segment acquired maximum revenue share in the Global Human Microbiome Market by Disease Type in 2021, thereby, achieving a market value of $398.07 Million by 2028. The need for particular bacterial-targeted therapy for infectious diseases has been underlined as awareness of the negative consequences of antibiotic utilization on the natural flora (such as disruptions) has grown. The increasing number of clinical studies for the development of target-specific microbiome-based therapeutics, as well as the rising prevalence of illnesses related to microbial dysbiosis as a result of antibiotic therapy, are the primary reasons driving the expansion of this market.
The Proteomics segment has shown growth rate of CAGR of 32.4% during (2022 - 2028). The growth of the segment is owing to the rising significance of proteomics. Proteomics is the evaluation of proteins on a broad scale. Proteins are essential components of living organisms, serving a variety of roles from forming muscle fibers to catalyzing food digestion to synthesizing and reproducing DNA.
The Therapeutics segment acquired maximum revenue share in the Global Human Microbiome Market by Application in 2021, thereby, achieving a market value of $720.5 Million by 2028. The primary reason driving the growth of this segment is an increase in funding for R&D into microbiome-based medicines around the world. Moreover, the rising employment of the human microbiome in therapeutics of various cardiovascular disorders is also increasing as a result of the rising incidences of cardiovascular diseases.
The Peptide market is experiencing a CAGR of 32.6% during (2022 - 2028). A peptide is a type of short amino acid chain. The amino acids in a peptide are linked together in a sequence by bonds known as peptide bonds. Peptides and proteins are typically distinguished by their shorter length, albeit the number of amino acids used to define a peptide and protein can be arbitrary.
The North America market dominated the Global Human Microbiome Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $426.4 Million by 2028. The Europe market is estimated to witness a CAGR of 31.7% during (2022 - 2028). Additionally, The Asia Pacific market would experience a CAGR of 33.2% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/human-microbiome-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Seres Therapeutics, Inc., 4D pharma plc, OptiBiotix Health Plc, Synlogic, Inc., Second Genome, Inc., Vedanta Biosciences, Inc., Finch Therapeutics Group, Inc., Ferring Holdings SA, and Enterome.
By Product
By Disease Type
By Technology
By Application
By Type
By Geography
Companies Profiled
Unique Offerings 
